<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESA AXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230909160734&amp;utm_campaign=pubmed- 2&amp;fc=20230708114047<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230909160734&amp;utm_campaign=pubmed-2&amp;fc=20230708114047" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 9 月 9 日星期六 20:07:35 +0000</lastbuilddate><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>通过血脑屏障的荷尔蒙把关控制着蚂蚁的种姓特定行为</title><link/>https://pubmed.ncbi.nlm.nih.gov/37683635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230909160734&amp;v=2.17.9.post6+86293ac<description>在这里，我们揭示了血脑屏障 (BBB) 在调节蚂蚁复杂的社会行为中发挥的意想不到的作用。利用 scRNA-seq，我们发现了一种称为保幼激素酯酶 (Jhe) 的关键激素降解酶位于 BBB 中。 ），我们表明这种定位控制着进入大脑的保幼激素（JH3）的水平。Jhe水平的操纵会重新编程蚂蚁种姓之间的大脑转录组。虽然蚂蚁Jhe被保留并在BBB内的细胞内发挥作用，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 24 日：S0092-8674(23)00856-5. doi: 10.1016/j.cell.2023.08.002. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">在这里，我们揭示了血脑屏障 (BBB) 在调节蚂蚁复杂的社会行为中发挥的意想不到的作用。利用 scRNA-seq，我们发现了一种称为保幼激素酯酶 (Jhe) 的关键激素降解酶位于 BBB 中。 ），我们表明这种定位控制着进入大脑的保幼激素（JH3）的水平。Jhe 水平的操纵会重新编程蚂蚁种姓之间的大脑转录组。尽管蚂蚁 Jhe 被保留并在 BBB 内发挥细胞内功能，但我们发现果蝇Jhe 天然存在于细胞外。蚂蚁 Jhe 在果蝇 BBB 中的异源表达改变了苍蝇的行为，以模仿蚂蚁中所看到的行为。最引人注目的是，操纵蚂蚁中的 Jhe 水平重新编程了工蚁种姓之间的复杂行为。因此，我们的研究揭示了一种非凡的、潜在的BBB 作为调节社会行为的神经激素途径的分子守门人的保守作用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37683635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37683635</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.002>10.1016/j.cell.2023.08.002</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37683635</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>鞠林洋</dc:creator><dc:creator>卡尔·M·格拉斯塔德</dc:creator><dc:creator>盛立红</dc:creator><dc:creator>扬科·戈斯波西奇</dc:creator><dc:creator>卡勒姆·J·金威尔</dc:creator><dc:creator>肖恩·M·戴维森</dc:creator><dc:creator>莎拉·D·科赫</dc:creator><dc:creator>罗伯托·博纳西奥</dc:creator><dc:creator>雪莱·伯杰</dc:creator><dc:date>2023-09-08</dc:date><dc:source>细胞</dc:source><dc:title>通过血脑屏障的荷尔蒙把关控制着蚂蚁的种姓特定行为</dc:title><dc:identifier>下午:37683635</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.002</dc:identifier></item><item><title> Patescibacteria 的基因操作为微生物暗物质和表生生活方式提供了机制见解</title><link/>https://pubmed.ncbi.nlm.nih.gov/37683634/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230909160734&amp;v=2.17.9.post6+86293ac<description> Patescibacteria，也称为候选辐射门 (CPR)，是一组多样化的细菌，构成了微生物暗物质中不成比例的大部分。它的少数培养成员主要属于糖杆菌，在宿主放线菌上作为表生菌生长。由于缺乏合适的工具，这种生活方式的遗传基础和 Patescibacteira 的其他独特特征仍未得到探索。在这里，我们表明糖细菌表现出天然的能力，并且我们利用... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 30 日：S0092-8674(23)00906-6. doi: 10.1016/j.cell.2023.08.017. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Patescibacteria，也称为候选辐射门 (CPR)，是一组多样化的细菌，构成了微生物暗物质中不成比例的大部分。它的少数培养成员主要属于糖杆菌，在宿主放线菌上作为表生菌生长。由于缺乏合适的工具，这种生活方式的遗传基础和 Patescibacteira 的其他独特特征仍未被探索。在这里，我们表明糖杆菌表现出天然的能力，并且我们利用这种特性进行基因操作。荧光蛋白标记的糖杆菌的成像提供了高时空解决伴随表生生长的现象，转座子插入测序（Tn-seq）全基因组筛选揭示了神秘的糖细菌基因对其宿主生长的贡献。最后，我们利用宏基因组数据提供基于蛋白质结构的尖端技术支持 Southlakia epibion​​ticum 菌株及其相应宿主以色列放线菌作为解锁表生生活方式分子基础的模型系统的生物信息资源。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37683634/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37683634</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.017>10.1016/j.cell.2023.08.017</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37683634</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>王亚熙</dc:creator><dc:creator>拉里·加拉格尔</dc:creator><dc:creator>皮娅·安德拉德</dc:creator><dc:creator>刘安迪</dc:creator><dc:creator>伊恩·R·汉弗莱斯</dc:creator><dc:creator>塞尔达·图卡斯兰</dc:creator><dc:creator>凯文·J·卡特勒</dc:creator><dc:creator>马里奥·L·阿列塔-奥尔蒂斯</dc:creator><dc:creator>李亚桥</dc:creator><dc:creator>马修·雷迪</dc:creator><dc:creator>杰弗里·麦克莱恩</dc:creator><dc:creator>钱聪</dc:creator><dc:creator>大卫·贝克</dc:creator><dc:creator>尼廷·S·巴利加</dc:creator><dc:creator>布鲁克彼得森</dc:creator><dc:creator>约瑟夫·D·穆古斯</dc:creator><dc:date>2023-09-08</dc:date><dc:source>细胞</dc:source><dc:title>Patescibacteria 的基因操作为微生物暗物质和表生生活方式提供了机制见解</dc:title><dc:identifier>下午:37683634</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.017</dc:identifier></item><item><title>环氧二十碳三烯酸通过 IFN-I 信号传导预防病毒性心肌炎的心脏功能障碍</title><link/>https://pubmed.ncbi.nlm.nih.gov/37681352/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230909160734&amp;v=2.17.9.post6+86293ac<description>心肌炎是一种具有挑战性的心脏炎症性疾病，需要更好地了解其发病机制以开发特异性药物疗法。环氧二十碳三烯酸（EET）是由花生四烯酸的 CYP（细胞色素 P450）酶合成的活性分子，并水解为活性较低的二羟基二十碳三烯酸由 sEH（可溶性环氧化物水解酶）产生的 EET 被认为具有抗炎活性。在这里，我们研究了 EET 是否具有免疫调节活性并发挥... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 9 月 8 日。doi：10.1161/CIRCRESAHA.123.322619。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">心肌炎是一种具有挑战性的心脏炎症性疾病，需要更好地了解其发病机制以开发特异性药物疗法。环氧二十碳三烯酸（EET）是由花生四烯酸的 CYP（细胞色素 P450）酶合成的活性分子，并水解为活性较低的二羟基二十碳三烯酸sEH（可溶性环氧化物水解酶）产生的 EET 被认为具有抗炎活性。在此，我们研究了 EET 是否具有免疫调节活性，并对柯萨奇 B3 病毒引起的心肌炎发挥保护作用。病毒感染心肌炎患者和心肌炎患者中的类二十烷酸环氧化物和二醇水平在小鼠心脏中，与柯萨奇 B3 病毒感染后 sEH 的表达和活性增加相关。使用 sEH 抑制剂可预防柯萨奇 B3 病毒引起的心脏功能障碍和炎症浸润。重要的是，EET/sEH 抑制剂治疗可减弱病毒感染或改善病毒感染通过激活 I 型 IFN（干扰素）信号传导来抵抗耐药性。在分子水平上，EET 增强了 GSK3β（糖原合酶激酶 3 beta）和 TBK1（TANK 结合激酶 1）之间的相互作用，以促进 IFN-β 的产生。我们的研究结果表明， EET 和 sEH 抑制剂可预防柯萨奇 B3 病毒引起的心肌炎的进展，特别是通过增加 IFN 的产生来促进病毒抵抗力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37681352/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37681352</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322619>10.1161/CIRCRESAHA.123.322619</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37681352</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>周周</dc:creator><dc:creator>张敏</dc:creator><dc:creator>赵成成</dc:creator><dc:creator>徐高</dc:creator><dc:creator>郑文</dc:creator><dc:creator>吴俊芳</dc:creator><dc:creator>陈陈</dc:creator><dc:creator>英格丽·弗莱明</dc:creator><dc:creator>胡炯</dc:creator><dc:creator>王道文</dc:creator><dc:date>2023-09-08</dc:date><dc:source>流通研究</dc:source><dc:title>环氧二十碳三烯酸通过 IFN-I 信号传导预防病毒性心肌炎的心脏功能障碍</dc:title><dc:identifier>下午：37681352</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322619</dc:identifier></item><item><title>阿哌沙班剂量与心房颤动和严重慢性肾脏病患者安全性和有效性结果的关系</title><link/>https://pubmed.ncbi.nlm.nih.gov/37681341/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230909160734&amp;v=2.17.9.post6+86293ac<description>结论：与 2.5 mg 相比，使用 5 mg 阿哌沙班与心房颤动和严重慢性肾脏病患者的出血风险较高相关，但中风/全身性栓塞或死亡风险没有差异，支持阿哌沙班的剂量建议欧洲药品管理局以肾功能为基础，与美国食品和药物管理局发布的不同。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 8 日。doi：10.1161/CIRCULATIONAHA.123.065614。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：美国食品和药物管理局和欧洲药品管理局根据肾功能对房颤患者阿哌沙班剂量的建议不一致。慢性肾病患者的最佳阿哌沙班剂量仍不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：通过使用来自 Optum Labs 数据仓库的去识别化电子健康记录数据，确定了 2013 年至 2021 年间开始服用阿哌沙班的心房颤动和慢性肾脏病 4/5 期患者。阿哌沙班剂量（5 与 2.5 mg），通过治疗权重的逆概率调整基线特征。使用细灰色次分布风险模型来解释死亡的竞争风险。使用 Cox 回归来检查阿哌沙班的死亡风险剂量。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 4313 名阿哌沙班新使用者中，1705 名（40%）接受 5 mg 治疗，2608 名（60%）接受 2.5 mg。接受 5 mg 阿哌沙班治疗的患者更年轻（平均年龄 72 岁与 80 岁），体重更大（95 岁与 80 岁）。 80 kg）和更高的血清肌酐（2.7 与 2.5 mg/dL）。平均估计肾小球滤过率在各组之间没有差异（24 与 24 mL·min <sup>-1</sup> ·1.73 m <sup>-2</sup> ）。治疗权重分析的逆概率，阿哌沙班 5 mg 与较高的出血风险相关（每 100 人年发生率 4.9 例与 2.9 例事件；发生率差异，每 100 人年 2.0 [95% CI，0.6-3.4] 例事件；次分布风险比，1.63 [95% CI, 1.04-2.54]）。阿哌沙班 5 mg 和 2.5 mg 组之间的卒中/全身性栓塞风险没有差异（每 100 人年分别有 3.3 例和 3.0 例事件；发生率差异为 0.2 [95 %] CI，-1.0 至 1.4] 每 100 人年事件；次分布风险比，1.01 [95% CI，0.59-1.73]），或死亡（每 100 人年 9.9 与 9.4 事件；发生率差异，0.5 [ 95每 100 人年发生事件 % CI，-1.6 至 2.6；风险比，1.03 [95% CI，0.77-1.38]）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与 2.5 mg 相比，使用 5 mg 阿哌沙班与心房颤动和严重慢性肾脏病患者的出血风险较高相关，但中风/全身性栓塞或死亡风险没有差异，支持阿哌沙班的剂量建议欧洲药品管理局以肾功能为基础，与美国食品和药物管理局发布的不同。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37681341/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37681341</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065614>10.1161/CIRCULATIONAHA.123.065614</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37681341</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>徐云文</dc:creator><dc:creator>亚历克斯·R·张</dc:creator><dc:creator>莱斯利·英克</dc:creator><dc:creator>玛拉·麦克亚当斯-德马科</dc:creator><dc:creator>摩根·E·格拉姆斯</dc:creator><dc:creator>申正林</dc:creator><dc:date>2023-09-08</dc:date><dc:source>循环</dc:source><dc:title>阿哌沙班剂量与心房颤动和严重慢性肾脏病患者安全性和有效性结果的关系</dc:title><dc:identifier>下午:37681341</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065614</dc:identifier></item><item><title>与参与高级护理改善捆绑付款相关的心血管支出、护理利用和临床结果的变化</title><link/>https://pubmed.ncbi.nlm.nih.gov/37681315/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230909160734&amp;v=2.17.9.post6+86293ac<description>结论：参与 BPCI-A 与模型中提供的心血管医疗事件或手术的支出减少、护理使用的改变或质量提高无关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 8 日。doi：10.1161/CIRCULATIONAHA.123.065109。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：高级护理改善捆绑付款 (BPCI-A) 是一项 Medicare 计划，旨在激励减少从住院开始到出院后 90 天结束的护理支出。心血管疾病是 Medicare 支出的重要驱动因素，是 BPCI-A 关注的领域之一。目前尚不清楚 BPCI-A 是否与模型中 3 种心血管医疗事件或 5 种心血管手术的支出减少或质量提高相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在这项回顾性队列研究中，我们使用 Medicare 索赔对 2017 年 1 月 1 日至 2019 年 9 月 30 日期间出院的患者进行了双重差分分析，以评估 BPCI-A 医院与匹配的非参与对照医院之间的差异。结果是与对照组相比，实施 BPCI-A 之前和之后 BPCI-A 医院心脏医疗和手术条件的支出差异变化。次要结果包括患者复杂性、护理使用、在家健康天数、再入院、和死亡率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：BPCI-A 医院心脏医疗事件的基线支出为 25 606 美元。BPCI-A 与对照医院心脏医疗事件支出的差异变化为 16 美元（95% CI，-228 美元至 261 美元； <i>P</i> = 0.90）。 BPCI-A 医院心脏手术发作的基线支出为 37 961 美元。心脏手术发作支出的差异变化为 171 美元（95% CI，-429 美元至 772 美元； <i>P</i> = 0.58）。医生护理方面的差异变化很小在 BPCI-A 与对照医院相比，90 天再入院率没有显着差异（差异变化，0.27% [95% CI，-0.25% 至对于医疗事件，差异变化为 0.80%]；对于手术事件，差异变化为 0.31% [95% CI，-0.98% 至 1.60%]）或死亡率（差异变化，对于手术事件，为 -0.14% [95% CI，-0.50% 至 0.23%]医疗事件；差异变化，-0.36% [95% CI，-1.25% 至 0.54%]（对于手术事件）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：参与 BPCI-A 与模型中提供的心血管医疗事件或手术的支出减少、护理使用的改变或质量提高无关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37681315/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37681315</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065109>10.1161 / CIRCULATIONAHA.123.065109</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37681315</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>苏克鲁特·沙希库玛</dc:creator><dc:creator>郑杰</dc:creator><dc:creator>约翰·奥拉夫</dc:creator><dc:creator>阿诺德·M·爱泼斯坦</dc:creator><dc:creator>凯伦·E·乔恩特·马多克斯</dc:creator><dc:date>2023-09-08</dc:date><dc:source>循环</dc:source><dc:title>与参与高级护理改善捆绑付款相关的心血管支出、护理利用和临床结果的变化</dc:title><dc:identifier>下午:37681315</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065109</dc:identifier></item><item><title>细胞外周分离是心脏传导的主要决定因素</title><link/>https://pubmed.ncbi.nlm.nih.gov/37681314/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230909160734&amp;v=2.17.9.post6+86293ac<description>结论：心脏传导与细胞外阻力无关，但与周围分离呈双相相关，这提供了证据表明，在正常间隙连接耦合条件下，CV 和细胞外容量之间的关系是由触觉机制决定的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 9 月 8 日。doi：10.1161/CIRCRESAHA.123.322567。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：心脏传导被认为是通过间隙连接发生的。最近的证据支持心电耦合是心脏电通讯的另一种机制。通过间隙连接的传导预测传导速度 (CV) 和大量细胞外电阻之间的直接关系。相比之下，心电耦合该理论的前提是 CV 与闰盘（如会周）内特殊细胞外裂隙的体积之间存在双相关系。我们的目标是确定心室 CV 与微米级和纳米级细胞外空间结构变化之间的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对灌注有渗透剂白蛋白、甘露醇、葡聚糖 70 kDa 或葡聚糖 2 MDa 的光学绘图豚鼠全心制剂的传导和 Cx43 (connexin43) 蛋白表达进行定量。对离体豚鼠心室肌​​细胞中的峰值钠电流进行定量通过阻抗谱量化细胞外电阻。在光漂白后荧光恢复的异源表达系统中评估细胞间通讯。通过透射电子显微照片量化会周宽度。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：甘露醇显着降低传播横向上的 CV，而白蛋白和两种葡聚糖则增加。白蛋白和 70 kDa 葡聚糖的组合相对于单独的白蛋白降低了 CV。甘露醇降低了细胞外阻力，但白蛋白没有改变，并且两种葡聚糖均增加。渗透剂未显着改变 Cx43 表达、电导和峰值钠电流。根据渗透剂，周周宽度按从最窄到最宽的顺序依次是白蛋白和葡聚糖，70 kDa；白蛋白或葡聚糖，70 kDa； 2 MDa；右旋糖酐，70 kDa 或无渗透剂，和甘露醇。以相同顺序比较时，CV 与周膜宽度呈双相相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：心脏传导与细胞外阻力无关，但与周围分离呈双相相关，这提供了证据表明，在正常间隙连接耦合条件下，CV 和细胞外容量之间的关系是由触觉机制决定的。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37681314/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37681314</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322567>10.1161/CIRCRESAHA.123.322567</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37681314</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>威廉·P·亚当斯</dc:creator><dc:creator>特里斯坦·B·赖希</dc:creator><dc:creator>赵亚军</dc:creator><dc:creator>拉斐尔·达瓦洛斯</dc:creator><dc:creator>莎拉·巴雷特</dc:creator><dc:creator>D瑞安·金</dc:creator><dc:creator>钱德拉·B·贝恩</dc:creator><dc:creator>卡特里娜·科鲁奇-张</dc:creator><dc:creator>格蕾丝·布莱尔</dc:creator><dc:creator>亚历山德拉·汉伦</dc:creator><dc:creator>艾丽西娅·洛萨诺</dc:creator><dc:creator>伦加萨伊·维拉拉哈万</dc:creator><dc:creator>万小平</dc:creator><dc:creator>伊莎贝尔·德谢尼</dc:creator><dc:creator>詹姆斯·W·史密斯</dc:creator><dc:creator>格雷戈里·S·霍克</dc:creator><dc:creator>罗伯特·G·古迪</dc:creator><dc:creator>史蒂文·波尔津</dc:creator><dc:date>2023-09-08</dc:date><dc:source>流通研究</dc:source><dc:title>细胞外周分离是心脏传导的主要决定因素</dc:title><dc:identifier>下午：37681314</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322567</dc:identifier></item><item><title>保留射血分数的临床和实验性心力衰竭中的克隆造血</title><link/>https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230909160734&amp;v=2.17.9.post6+86293ac<description>结论：CH 与 HFpEF 患者较差的心功能和预后相关，Tet2 介导的 CH 小鼠实验模型显示出更多的 HFpEF 特征。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 8 日。doi：10.1161/CIRCULATIONAHA.123.064170。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：克隆造血（CH）是由一系列非恶性驱动基因突变引起的，可导致免疫细胞功能改变和慢性疾病，并且与射血分数降低的心力衰竭（HF）患者的较差预后相关。然而，CH 在射血分数保留的心力衰竭 (HFpEF) 预后中的作用尚未得到充分研究。本研究旨在描述 HFpEF 患者的 CH 特征，并阐明其在小鼠模型中的因果作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用一组 20 个候选 CH 驱动基因和 0.5% 的变异等位基因频率截止值，超深纠错测序在 81 名 HFpEF 患者（平均年龄，71±6 岁；射血分数，63± 5%）和 36 名未诊断为 HFpEF 的对照（平均年龄，74±7 岁；射血分数，61.5±8%）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：与对照组相比，HFpEF 患者队列中<i>TET2</i>介导的 CH 丰富（分别为 12% 与 0%； <i>P</i> = 0.02）。在 HFpEF 队列中，CH 患者在 E 方面表现出加剧的舒张功能障碍。与无 CH 的患者相比，E/A（分别为 14.9 与 11.7； <i>P</i> = 0.0096）和 E/A（分别为 1.69 与 0.89； <i>P</i> = 0.0206）。CH 与舒张功能障碍加剧的相关性在验证队列中得到证实59 名 HFpEF 患者。据此，与不伴有 CH 且年龄≥70 岁的 HFpEF 患者相比，年龄≥70 岁的 HFpEF 患者在 5 年心血管相关住院率方面的预后较差（风险比为 5.06； <i>P</i> = 0.042）。年龄 ≥70 岁。为了研究 CH 在 HFpEF 中的因果作用，非条件化小鼠接受了<i>Tet2</i>野生型或<i>Tet2</i>缺陷型骨髓的过继移植，随后接受高脂肪饮食/L-NAME (N <sub>ω</sub> -硝基-L-精氨酸甲酯）联合治疗诱导 HFpEF 的特征。这种<i>Tet2</i> -CH 模型通过心脏重量/胫骨长度和心肌细胞大小加剧了心脏肥大，通过 E/e&#39; 和左心室舒张末压加剧了舒张功能障碍，和心脏纤维化与<i>Tet2-</i>野生型状况相比。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：CH 与 HFpEF 患者较差的心功能和预后相关， <i>Tet2</i>介导的 CH 小鼠实验模型显示出更多的 HFpEF 特征。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37681311</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064170>10.1161/CIRCULATIONAHA.123.064170</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37681311</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>杰西·科克伦</dc:creator><dc:creator>由良义光</dc:creator><dc:creator>马克·C·塞尔</dc:creator><dc:creator>希瑟·多维亚克</dc:creator><dc:creator>阿里尔·H·波利齐奥</dc:creator><dc:creator>新井由香</dc:creator><dc:creator>新井阳平</dc:creator><dc:creator>堀谷庆太</dc:creator><dc:creator>朴恩妃</dc:creator><dc:creator>尼古拉斯·W·查夫金</dc:creator><dc:creator>阿努普里特·库尔</dc:creator><dc:creator>佐野宗一</dc:creator><dc:creator>尼廷·马哈詹</dc:creator><dc:creator>梅根·埃文斯</dc:creator><dc:creator>马哈莉亚·胡巴</dc:creator><dc:creator>纳迪亚·马丁内斯</dc:creator><dc:creator>孙汉娜</dc:creator><dc:creator>潘英浩</dc:creator><dc:creator>凯伦·希尔斯基</dc:creator><dc:creator>斯特凡诺·托尔多</dc:creator><dc:creator>安东尼奥·阿巴特</dc:creator><dc:creator>托德·德鲁利</dc:creator><dc:creator>弗雷德里克·鲁伯格</dc:creator><dc:creator>马修·毛雷尔</dc:creator><dc:creator>贾斯汀·埃泽科维茨</dc:creator><dc:creator>贾森·RB·戴克</dc:creator><dc:creator>肯尼思·沃尔什</dc:creator><dc:date>2023-09-08</dc:date><dc:source>循环</dc:source><dc:title>保留射血分数的临床和实验性心力衰竭中的克隆造血</dc:title><dc:identifier>下午:37681311</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064170</dc:identifier></item><item><title>假性缺氧增加 p300 诱导的糖酵解促进心脏衰老</title><link/>https://pubmed.ncbi.nlm.nih.gov/37681309/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230909160734&amp;v=2.17.9.post6+86293ac<description>结论：总而言之，我们的结果表明糖酵解途径增强剂的表观遗传失调如何可能成为治疗老年人心力衰竭的潜在靶点。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 9 月 8 日。doi：10.1161/CIRCRESAHA.123.322676。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">理由：心力衰竭在老年人中很常见。心肌细胞的代谢重塑是心脏功能随年龄增长而不可避免恶化的基础：糖酵解增加，但以氧化磷酸化为代价，导致能量不足，导致收缩力受损。更好地了解这种代谢转换的机制对于扭转这种情况可能至关重要。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：研究 3 种组蛋白修饰（H3K27ac、H3K27me3 和 H3K4me1）在衰老心脏代谢重塑中的作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们报告了一组物种保守的增强子，这些增强子与心肌细胞中与年龄相关的代谢重塑相关的转录变化相关<i>。Hk2</i>增强子区域（一个关键的糖酵解途径基因）的激活是在老年小鼠心脏中通过假性缺氧促进的。因此，通过增加转录共激活因子 p300（E1A 相关结合蛋白 p300）/CBP（CREB ​​结合蛋白）的活性，缺氧相关基因在正常 O <sub>2</sub>水平下表达。衰老导致有氧运动增加、糖酵解代谢状态减少、心脏收缩力改善以及心脏衰退的总体减缓。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：总而言之，我们的结果表明糖酵解途径增强剂的表观遗传失调如何可能成为治疗老年人心力衰竭的潜在靶点。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37681309/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37681309</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322676>10.1161/CIRCRESAHA.123.322676</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37681309</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>西蒙·塞里奥</dc:creator><dc:creator>克里斯蒂娜·帕吉亚塔基斯</dc:creator><dc:creator>埃莱特拉·穆索里诺</dc:creator><dc:creator>阿里安娜·费利塞塔</dc:creator><dc:creator>皮耶路易吉·卡鲁洛</dc:creator><dc:creator>哈维尔·劳拉·弗朗西斯</dc:creator><dc:creator>劳拉爸爸</dc:creator><dc:creator>贾科莫·罗齐</dc:creator><dc:creator>尼科洛·萨尔瓦拉尼</dc:creator><dc:creator>米歇尔·米拉戈利</dc:creator><dc:creator>罗莎尔巴·戈尔纳蒂</dc:creator><dc:creator>乔瓦尼·贝尔纳迪尼</dc:creator><dc:creator>詹路易吉·孔多雷利</dc:creator><dc:creator>罗伯托·帕派特</dc:creator><dc:date>2023-09-08</dc:date><dc:source>流通研究</dc:source><dc:title>假性缺氧增加 p300 诱导的糖酵解促进心脏衰老</dc:title><dc:identifier>下午:37681309</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322676</dc:identifier></item><item><title>心中的苹果：罕见的心脏高免疫球蛋白E综合征</title><link/>https://pubmed.ncbi.nlm.nih.gov/37680109/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230909160734&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 8:ehad565.doi: 10.1093/eurheartj/ehad565. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37680109/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37680109</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad565>10.1093/eurheartj/ehad565</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37680109</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>洁银</dc:creator><dc:creator>刘晓航</dc:creator><dc:creator>陈伟</dc:creator><dc:date>2023-09-08</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心中的苹果：罕见的心脏高免疫球蛋白E综合征</dc:title><dc:identifier>下午:37680109</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad565</dc:identifier></item><item><title>抑制肝脏血管紧张素原合成作为高血压治疗的新方法：前景与挑战</title><link/>https://pubmed.ncbi.nlm.nih.gov/37680108/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230909160734&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 8:ehad593.doi: 10.1093/eurheartj/ehad593. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37680108/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37680108</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad593>10.1093/eurheartj/ehad593</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37680108</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>乔凡娜·柳佐</dc:creator><dc:creator>马西莫·沃尔普</dc:creator><dc:date>2023-09-08</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>抑制肝脏血管紧张素原合成作为高血压治疗的新方法：前景与挑战</dc:title><dc:identifier>下午：37680108</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad593</dc:identifier></item><item><title>更年期-生物学、后果、支持护理和治疗选择</title><link/>https://pubmed.ncbi.nlm.nih.gov/37678251/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230909160734&amp;v=2.17.9.post6+86293ac<description>更年期是指卵巢功能停止，生殖激素产生丧失，生育能力不可逆转地丧失。它是生殖衰老的自然组成部分。更年期的生理机制很复杂，目前尚未完全了解。全球范围内，更年期发生在 49 岁左右, 具有地理和种族差异。更年期过渡的荷尔蒙变化可能会导致症状和长期系统性影响，主要是对心脏代谢和……的不利影响。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 5 日：S0092-8674(23)00905-4.doi: 10.1016/j.cell.2023.08.016.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">更年期是指卵巢功能停止，生殖激素产生丧失，生育能力不可逆转地丧失。它是生殖衰老的自然组成部分。更年期的生理机制很复杂，目前尚未完全了解。全球范围内，更年期发生在 49 岁左右更年期过渡期间的荷尔蒙变化可能会导致症状和长期的全身影响，主要是对心脏代谢和肌肉骨骼健康的不利影响。针对令人烦恼的更年期症状最有效的治疗方法是循证的更年期激素疗法（MHT），它可以减少骨质流失，可能对心脏代谢有好处。基于证据的非激素干预也可用于缓解症状。治疗应个体化，共同决策。需要包括围绝经期妇女在内的研究来确定治疗方案的有效性和安全性。进一步研究对于改善更年期护理以及指导政策和临床实践至关重要。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37678251/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37678251</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.016>10.1016/j.cell.2023.08.016</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37678251</guid><pubDate> Thu, 07 Sep 2023 06:00:00 -0400</pubDate><dc:creator>苏珊·R·戴维斯</dc:creator><dc:creator>乔安·平克顿</dc:creator><dc:creator>纳内特·桑托罗</dc:creator><dc:creator>托马索·西蒙奇尼</dc:creator><dc:date>2023-09-07</dc:date><dc:source>细胞</dc:source><dc:title>更年期-生物学、后果、支持护理和治疗选择</dc:title><dc:identifier>下午：37678251</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.016</dc:identifier></item><item><title>每日步数与全因死亡率和心血管事件的关系</title><link/>https://pubmed.ncbi.nlm.nih.gov/37676198/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230909160734&amp;v=2.17.9.post6+86293ac<description>结论：每天少走约 2,600 步和约 2,800 步即可产生显着的死亡率和 CVD 益处，并且逐渐将风险降低至约 8,800 步/天和约 7,200 步/天。步频。鉴于步数计数的概念易于理解，这些发现可以扩展当代的身体活动处方。（每日步数与健康结果之间的剂量反应关系：系统回顾... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 26 日：S0735-1097(23)06400-8。doi：10.1016/j.jacc.2023.07.029。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：改善健康的最小和最佳每日步数仍不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：进行荟萃分析以量化一般人群中客观测量的步数指标的剂量反应关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从开始到 2022 年 10 月检索电子数据库。主要结局包括全因死亡率和心血管疾病 (CVD)。使用广义最小二乘法和随机效应模型对研究结果进行分析。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总共纳入了来自 12 项研究的 111,309 名受试者。每天 2,517 步的全因死亡率风险显着降低（调整后 HR [aHR]：0.92；95% CI：0.84-0.999）和每天 2,735 步的全因死亡率风险显着降低。 . 与 2,000 步/天（参考）相比，对于 CVD 事件（aHR：0.89；95% CI：0.79-0.999）。额外的步骤导致全因死亡率和 CVD 事件的非线性风险降低，最佳剂量为 8,763（aHR）分别为：0.40；95% CI：0.38-0.43）和 7,126 步/天（aHR：0.49；95% CI：0.45-0.55）。从低步频到中步频或高步频的增量与以下风险降低独立相关：性别并不影响剂量反应关联，但在对评估设备和佩戴位置进行分层后，与计步器和腕戴式加速度计相比，髋部佩戴式加速度计的风险显着降低。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：每天少走约 2,600 步和约 2,800 步即可产生显着的死亡率和 CVD 益处，并且逐渐将风险降低至约 8,800 步/天和约 7,200 步/天。步频。鉴于步数计数的概念易于理解，这些发现可以扩展当代的身体活动处方。（每日步数与健康结果之间的剂量反应关系：系统回顾和荟萃分析；CRD42021244747）。</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37676198/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37676198</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.07.029>10.1016/j.jacc.2023.07.029</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37676198</guid><pubDate> Thu, 07 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Niels A Stens</dc:creator><dc:creator> Esmée A Bakker</dc:creator><dc:creator> Asier Mañas</dc:creator><dc:creator> Laurien M Buffart</dc:creator><dc:creator> Francisco B Ortega</dc:creator><dc:creator> Duck-Chul Lee</dc:creator><dc:creator> Paul D Thompson</dc:creator><dc:creator> Dick HJ Thijssen</dc:creator><dc:creator> Thijs MH Eijsvogels</dc:creator><dc:date> 2023-09-07</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Relationship of Daily Step Counts to All-Cause Mortality and Cardiovascular Events</dc:title><dc:identifier> pmid:37676198</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.029</dc:identifier></item><item><title> Reducing Mortality and Cardiovascular Disease: Stepping Up Our Game</title><link/> https://pubmed.ncbi.nlm.nih.gov/37676197/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230909160734&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Aug 28:S0735-1097(23)06401-X. doi: 10.1016/j.jacc.2023.08.007. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37676197/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37676197</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.08.007>10.1016/j.jacc.2023.08.007</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37676197</guid><pubDate> Thu, 07 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Carl J Lavie</dc:creator><dc:creator> Charles A German</dc:creator><dc:creator> Fabian Sanchis-Gomar</dc:creator><dc:date> 2023-09-07</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Reducing Mortality and Cardiovascular Disease: Stepping Up Our Game</dc:title><dc:identifier> pmid:37676197</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.007</dc:identifier></item><item><title> Correction to: Lifelong endurance exercise and its relation with coronary atherosclerosis</title><link/> https://pubmed.ncbi.nlm.nih.gov/37675842/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230909160734&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 7:ehad546. doi: 10.1093/eurheartj/ehad546. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37675842/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37675842</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad546>10.1093/eurheartj/ehad546</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37675842</guid><pubDate> Thu, 07 Sep 2023 06:00:00 -0400</pubDate><dc:date> 2023-09-07</dc:date><dc:source> European heart journal</dc:source><dc:title> Correction to: Lifelong endurance exercise and its relation with coronary atherosclerosis</dc:title><dc:identifier> pmid:37675842</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad546</dc:identifier></item><item><title> Correction to: 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC)</title><link/> https://pubmed.ncbi.nlm.nih.gov/37675631/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230909160734&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 7:ehad577. doi: 10.1093/eurheartj/ehad577. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37675631/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37675631</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad577>10.1093/eurheartj/ehad577</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37675631</guid><pubDate> Thu, 07 Sep 2023 06:00:00 -0400</pubDate><dc:date> 2023-09-07</dc:date><dc:source> European heart journal</dc:source><dc:title> Correction to: 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC)</dc:title><dc:identifier> pmid:37675631</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad577</dc:identifier></item><item><title> Redirecting immune, lipid, and metabolic drivers of early cardiovascular disease: the RESET cohort study and randomized trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37675563/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230909160734&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 7:ehad543. doi: 10.1093/eurheartj/ehad543. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37675563/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37675563</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad543>10.1093/eurheartj/ehad543</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37675563</guid><pubDate> Thu, 07 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Mayank Dalakoti</dc:creator><dc:creator> Roger Foo</dc:creator><dc:creator> RESET Consortium</dc:creator><dc:date> 2023-09-07</dc:date><dc:source> European heart journal</dc:source><dc:title> Redirecting immune, lipid, and metabolic drivers of early cardiovascular disease: the RESET cohort study and randomized trial</dc:title><dc:identifier> pmid:37675563</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad543</dc:identifier></item><item><title> ADAMTS-7 Modulates Atherosclerotic Plaque Formation by Degradation of TIMP-1</title><link/> https://pubmed.ncbi.nlm.nih.gov/37675562/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230909160734&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: ADAMTS-7, which is induced in unstable atherosclerotic plaques, decreases TIMP-1 stability reducing its inhibitory effect on MMP-9, which is known to promote collagen degradation and is likewise associated with coronary artery disease. Disrupting the interaction of ADAMTS-7 and TIMP-1 might be a strategy to increase collagen content and plaque stability for the reduction of atherosclerosis-related events. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Sep 7. doi: 10.1161/CIRCRESAHA.123.322737. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: The <i>ADAMTS7</i> locus was genome-wide and significantly associated with coronary artery disease. Lack of the ECM (extracellular matrix) protease ADAMTS-7 (A disintegrin and metalloproteinase-7) was shown to reduce atherosclerotic plaque formation. Here, we sought to identify molecular mechanisms and downstream targets of ADAMTS-7 mediating the risk of atherosclerosis. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Targets of ADAMTS-7 were identified by high-resolution mass spectrometry of atherosclerotic plaques from Apoe <sup>-/-</sup> and Apoe <sup>-/-</sup> Adamts7 <sup>-/-</sup> mice. ECM proteins were identified using solubility profiling. Putative targets were validated using immunofluorescence, in vitro degradation assays, coimmunoprecipitation, and Förster resonance energy transfer-based protein-protein interaction assays. <i>ADAMTS7</i> expression was measured in fibrous caps of human carotid artery plaques. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: In humans, <i>ADAMTS7</i> expression was higher in caps of unstable as compared to stable carotid plaques. Compared to Apoe <sup>-/-</sup> mice, atherosclerotic aortas of Apoe <sup>-/-</sup> mice lacking Adamts-7 (Apoe <sup>-/-</sup> Adamts7 <sup>-/-</sup> ) contained higher protein levels of Timp-1 (tissue inhibitor of metalloprotease-1). In coimmunoprecipitation experiments, the catalytic domain of ADAMTS-7 bound to TIMP-1, which was degraded in the presence of ADAMTS-7 in vitro. ADAMTS-7 reduced the inhibitory capacity of TIMP-1 at its canonical target MMP-9 (matrix metalloprotease-9). As a downstream mechanism, we investigated collagen content in plaques of Apoe <sup>-/-</sup> and Apoe <sup>-/-</sup> Adamts7 <sup>-/-</sup> mice after the Western diet. Picrosirius red staining of the aortic root revealed less collagen as a readout of higher MMP-9 activity in Apoe <sup>-/-</sup> as compared to Apoe <sup>-/-</sup> Adamts7 <sup>-/-</sup> mice. To facilitate high-throughput screening for ADAMTS-7 inhibitors with the aim of decreasing TIMP-1 degradation, we designed a Förster resonance energy transfer-based assay targeting the ADAMTS-7 catalytic site. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: ADAMTS-7, which is induced in unstable atherosclerotic plaques, decreases TIMP-1 stability reducing its inhibitory effect on MMP-9, which is known to promote collagen degradation and is likewise associated with coronary artery disease. Disrupting the interaction of ADAMTS-7 and TIMP-1 might be a strategy to increase collagen content and plaque stability for the reduction of atherosclerosis-related events.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37675562/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37675562</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.123.322737>10.1161/CIRCRESAHA.123.322737</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37675562</guid><pubDate> Thu, 07 Sep 2023 06:00:00 -0400</pubDate><dc:creator> M Amin Sharifi</dc:creator><dc:creator> Michael Wierer</dc:creator><dc:creator> Tan An Dang</dc:creator><dc:creator> Jelena Milic</dc:creator><dc:creator> Aldo Moggio</dc:creator><dc:creator> Nadja Sachs</dc:creator><dc:creator> Moritz von Scheidt</dc:creator><dc:creator> Julia Hinterdobler</dc:creator><dc:creator> Philipp Müller</dc:creator><dc:creator> Julia Werner</dc:creator><dc:creator> Barbara Stiller</dc:creator><dc:creator> Zouhair Aherrahrou</dc:creator><dc:creator> Jeanette Erdmann</dc:creator><dc:creator> Andrea Zaliani</dc:creator><dc:creator> Mira Graettinger</dc:creator><dc:creator> Jeanette Reinshagen</dc:creator><dc:creator> Sheraz Gul</dc:creator><dc:creator> Philip Gribbon</dc:creator><dc:creator> Lars Maegdefessel</dc:creator><dc:creator> Jürgen Bernhagen</dc:creator><dc:creator> Hendrik B Sager</dc:creator><dc:creator> Matthias Mann</dc:creator><dc:creator> Heribert Schunkert</dc:creator><dc:creator> Thorsten Kessler</dc:creator><dc:date> 2023-09-07</dc:date><dc:source> Circulation research</dc:source><dc:title> ADAMTS-7 Modulates Atherosclerotic Plaque Formation by Degradation of TIMP-1</dc:title><dc:identifier> pmid:37675562</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322737</dc:identifier></item><item><title> Cardiovascular disease prevention in people living with HIV: from REPRIEVE to a statin of grace</title><link/> https://pubmed.ncbi.nlm.nih.gov/37674466/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230909160734&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 7:ehad594. doi: 10.1093/eurheartj/ehad594. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37674466/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37674466</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad594>10.1093/eurheartj/ehad594</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37674466</guid><pubDate> Thu, 07 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Rocco Vergallo</dc:creator><dc:creator> Carlo Patrono</dc:creator><dc:date> 2023-09-07</dc:date><dc:source> European heart journal</dc:source><dc:title> Cardiovascular disease prevention in people living with HIV: from REPRIEVE to a statin of grace</dc:title><dc:identifier> pmid:37674466</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad594</dc:identifier></item><item><title> Reducing embolic events in left-sided infective endocarditis by surgery: the earlier the better</title><link/> https://pubmed.ncbi.nlm.nih.gov/37674408/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230909160734&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 7:ehad548. doi: 10.1093/eurheartj/ehad548. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37674408/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37674408</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad548>10.1093/eurheartj/ehad548</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37674408</guid><pubDate> Thu, 07 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Andrew Wang</dc:creator><dc:date> 2023-09-07</dc:date><dc:source> European heart journal</dc:source><dc:title> Reducing embolic events in left-sided infective endocarditis by surgery: the earlier the better</dc:title><dc:identifier> pmid:37674408</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad548</dc:identifier></item><item><title> Unravelling the heart&#39;s comic drama: can TLRs and hyaluronan metabolism stoke neutrophil rage in acute coronary syndrome?</title><link/> https://pubmed.ncbi.nlm.nih.gov/37674369/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230909160734&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 7:ehad455. doi: 10.1093/eurheartj/ehad455. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37674369/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37674369</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad455>10.1093/eurheartj/ehad455</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37674369</guid><pubDate> Thu, 07 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Grégory Franck</dc:creator><dc:date> 2023-09-07</dc:date><dc:source> European heart journal</dc:source><dc:title> Unravelling the heart&#39;s comic drama: can TLRs and hyaluronan metabolism stoke neutrophil rage in acute coronary syndrome?</dc:title><dc:identifier> pmid:37674369</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad455</dc:identifier></item><item><title> Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction</title><link/> https://pubmed.ncbi.nlm.nih.gov/37674356/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230909160734&amp;v=2.17.9.post6+86293ac<description> For decades, heart failure with preserved ejection fraction (HFpEF) proved an elusive entity to treat. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to reduce the composite of heart failure hospitalization or cardiovascular death in patients with HFpEF in the landmark DELIVER and EMPEROR-Preserved trials. While improvements in blood sugar, blood pressure, and attenuation of kidney disease progression all may play some role, preclinical and translational research have... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 7:ehad389. doi: 10.1093/eurheartj/ehad389. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> For decades, heart failure with preserved ejection fraction (HFpEF) proved an elusive entity to treat. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to reduce the composite of heart failure hospitalization or cardiovascular death in patients with HFpEF in the landmark DELIVER and EMPEROR-Preserved trials. While improvements in blood sugar, blood pressure, and attenuation of kidney disease progression all may play some role, preclinical and translational research have identified additional mechanisms of these agents. The SGLT2 inhibitors have intriguingly been shown to induce a nutrient-deprivation and hypoxic-like transcriptional paradigm, with increased ketosis, erythropoietin, and autophagic flux in addition to altering iron homeostasis, which may contribute to improved cardiac energetics and function. These agents also reduce epicardial adipose tissue and alter adipokine signalling, which may play a role in the reductions in inflammation and oxidative stress observed with SGLT2 inhibition. Emerging evidence also indicates that these drugs impact cardiomyocyte ionic homeostasis although whether this is through indirect mechanisms or via direct, off-target effects on other ion channels has yet to be clearly characterized. Finally, SGLT2 inhibitors have been shown to reduce myofilament stiffness as well as extracellular matrix remodelling/fibrosis in the heart, improving diastolic function. The SGLT2 inhibitors have established themselves as robust, disease-modifying therapies and as recent trial results are incorporated into clinical guidelines, will likely become foundational in the therapy of HFpEF.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37674356/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230909160734&v=2.17.9.post6+86293ac">37674356</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad389>10.1093/eurheartj/ehad389</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37674356</guid><pubDate> Thu, 07 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Arjun K Pandey</dc:creator><dc:creator> Deepak L Bhatt</dc:creator><dc:creator> Avinash Pandey</dc:creator><dc:creator> Nikolaus Marx</dc:creator><dc:creator> Francesco Cosentino</dc:creator><dc:creator> Ambarish Pandey</dc:creator><dc:creator> Subodh Verma</dc:creator><dc:date> 2023-09-07</dc:date><dc:source> European heart journal</dc:source><dc:title> Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction</dc:title><dc:identifier> pmid:37674356</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad389</dc:identifier></item></channel></rss>